Synergy Immunotherapy Meeting

Immunotherapy and Cell Therapy Synergy Cluster Meeting 

08:30 – Gathering & Refreshments

09:00 – Introduction
     Elad Jacoby and Eric Shifrut

Clinical State and Barriers

09:10 – Ronnie Shapira (Sheba)
     Unmet needs in melanoma journey

09:20 – Raya Leibowitz (Shamir)
 

09:30 – Ido Wolf (TASMC)
 

09:40 – Ronit Marcus (Sheba)
     CD19 CAR applications in hematology and beyond

09:50 – Ron Ram (TASMC)
 

Scientific Progress

10:00 – Eric Shifrut (TAU / TASMC)
     CRISPR platforms for T cell therapies

10:10 – Asaf Madi (TAU)
     Enhancing immunotherapy: mechanistic insights and rationale for combination approaches

10:20 – Adi Barzel (TAU)
     Lymphocyte engineering ex vivo and in vivo

10:30 – Anat Globerson Levin (TASMC)
     Novel strategies for targeting ovarian tumors with dual CAR T cells – a clinical trial perspective

10:40 – Alessio Nahmad (Rabin)
     Harnessing tumor-infiltrating lymphocytes to produce engineered polyclonal antibody therapies

10:50 – Merav Cohen (TAU)
     Immune cell-mediated cellular communications drive tissue development and disease

11:00 – Gal Cafri (Sheba)

11:10 – Ariel Munitz (TAU)
    Roles of eosinophils and type 2 immunity in the tumor microenvironment

Clinical Production Platforms

11:20 – Shimrit Suliman (TASMC)
     Introduction to GMP

11:30 – Jonathan Essensten (Sheba)
     Introduction to the ABC

11:40 – Einav Vax (Sheba)
     VST production

11:50 – Michael Besser (Rabin)
     The Samueli Institute at RMC: a new player in I/O

12:00 – Open Table Discussions and Light Lunc